Clinical trial
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
NCT00379197 · Masonic Cancer Center, University of Minnesota, Other · Terminated
Key facts
| NCT number | NCT00379197 |
|---|---|
| Title | Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer |
| Official title | Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | naltrexone, PET scan |
| Enrollment | 13 |
| Start date | Jul 1, 2006 |
| Primary completion | May 1, 2013 |
| Completion | May 1, 2013 |
| First posted | Sep 21, 2006 |
| Last update posted | Dec 28, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: